SCN9A gene encodes voltage-gated sodium channel Na V 1.7 and is associated with a group of heterogeneous phenotypes. Heterozygous gain-of-function SCN9A mutations have been linked to inherited erythromelalgia (IEM), paroxysmal extreme pain disorder (PEPD), and small-fiber neuropathy (SFN), while recessive loss-of-function SCN9A mutations have been linked to congenital insensitivity to pain (CIP). Recently, a heterozygous SCN9A mutation was found to be responsible for generalized epilepsy with febrile seizures plus (GEFS+) in a large pedigree.1 SCN9A variants have also been suggested as a genetic modifier in SCN1A mutation-associated GEFS+ and a possible susceptibility gene for Dravet syndrome [1, 2] . However, the exact role of SCN9A in seizure disorders is still complicated and debating [2] . We report a pedigree diagnosed as GEFS+ with a heterozygous mutation (Q10R) in SCN9A gene.
Case report
The proband (III:1) was a six-year-old boy, who was born at term after an unremarkable pregnancy and had normal early psychomotor development. He experienced febrile and afebrile seizures for more than 10 times since the age of two. All the seizures presented as generalized tonic-clonic seizures for several minutes. No obvious abnormality was found on neurological examination. Brain MRI and ambulatory EEG were unremarkable. His younger brother (III:2) was two years old. He was also born at term after an unremarkable pregnancy and had normal early psychomotor development. He experienced febrile and afebrile seizures for 3 times at the age of two. In the further pedigree investigation, the proband's mother (II:2) and grandmother (I:2) both reported febrile seizures in their childhood (Fig. 1) . The febrile seizures of the mother (II:2) and grandmother (I:2) remitted spontaneously by the age of ten. There was no other symptom or sign found on the mother (II:2) and grandmother (I:2), except that both of them reported poor memory.
To identify the causative gene of this GEFS+ pedigree, genetic test was performed on the proband using a Next-generation sequencing panel containing 480 epilepsy-related genes. A heterozygous missense mutation c.29A > G (p.Q10R) in SCN9A gene (reference transcript: NM_002977) was detected. This mutation was further confirmed by Sanger sequencing, detected in the affected mother (II:2) and brother (III:3), and not detected in the unaffected father (II:3) ( Fig. 1 ) Interestingly, this missense mutation Q10R and another missense mutation in the same amino acid site À c.28C > A (p.Q10K) were previously reported as causative mutations of IEM patients. c.29A > G (p.Q10R) was absent in 200 alleles from normal Chinese controls, which supported it was unlikely to be a polymorphism [3] . After follow-up questioning, none of these four patients (III:1, III:2, II:2 and I:2) reported any easily recognized extreme pain, warmth or redness phenotypes. Other genes associated with febrile seizures and GEFS+ like SCN1A, GABRG2, CPA6, GABRD and SCN1B were also included in the panel and no candidate mutation in these genes was detected. Based on these clinical symptoms, pedigree history and genetic analysis, we proposed that this is a GEFS+ pedigree associated with the Q10R mutation in SCN9A.
Discussion
Clinical heterogeneity is common in genetic diseases. Even affected members in a GEFS+ pedigree with the same SCN1A mutation could present different phenotypes from febrile seizures to Dravet syndrome, a severe epileptic encephalopathy. SCN9A associated phenotypes in human were varied and included IEM, PEPD, SFN and CIP. SCN9A encodes Na V 1.7, which is mainly expressed in neurons of the dorsal root ganglia and has preliminarily been classified as a peripheral nervous system channel. However, expression of Na V 1.7 in brain (embryonic hippocampal neurons) was also reported and suggested a role in the central nervous system [4] . A confirmed large pedigree of GEFS + and several sporadic patients with febrile seizures associated with mutations in SCN9A were reported, which supported seizure disorders as a fifth phenotype of SCN9A. However, the reports about the role of SCN9A in seizure disorders were rare and still debating. Singh et al. suggested SCN9A as a potential modifier gene to Dravet syndrome in patients with SCN1A mutations [1] . Mulley et al. found that rare variants in SCN9A were significantly enriched in Dravet syndrome, but damaging variants were similar between Dravet syndrome patients and normal controls, which supported a role for SCN9A in genetic susceptibility to Dravet syndrome [2] .
Although it seems complicated about the role of SCN9A in Dravet syndrome, the role of SCN9A in autosomal dominant febrile seizures or GEFS+ is simple. A large GEFS+ pedigree associated with SCN9A mutation with a quite high penetrance for about 95% was reported, which suggested a monogenic pattern in GEFS+ [1] . However, other febrile seizures or GEFS+ patients associated with SCN9A mutations were almost sporadic or only with one firstdegree relative, which can not offer further powerful evidence for the role of SCN9A in autosomal dominant febrile seizures or GEFS+. We report a GEFS+ pedigree including four patients, which was associated with SCN9A mutation. This report further supports that SCN9A mutations are associated with GEFS+ with a monogenic pattern.
Interestingly, the causative mutation in our pedigree Q10R and another mutation in the same amino acid site (Q10K) were reported in late-onset (age of 14 and 35 years) IEM patients [3] . To our knowledge, there is no mutation in SCN9A associated with seizure disorders also found in IEM, PEPD, SFN or CIP patients previously. The underlying mechanism of such heterogeneity was still unclear. Functional study using current-clamp revealed that expression of Q10R mutation induced hyperexcitability on dorsal root ganglion neurons, and this increase in excitability was smaller than the change produced by an early-onset (usually before age of 6 years) IEM mutation I848T [3] . A genotype-phenotype correlation was proposed that more increased excitability on dorsal root ganglion neurons was associated with earlier onset age of IEM. As SCN9A is also expressed in brain, we speculate that the Q10R mutation also increases the central nervous system excitability and causes the phenotype of seizure disorders. There may be a similar genotype-phenotype correlation that more increased central nervous system excitability is associated with more severe seizure disorders (from febrile seizures to Dravet syndrome). Although the mother and the grandmother were older than 30 years and 50 years respectively, no symptoms of IEM were complained so far. As the hyperexcitability on dorsal root ganglion neurons induced by Q10R was smaller than other mutation like I848T, reduced penetrance of IEM symptoms could be considered to explain the absence of IEM symptoms in our pedigree. On the other hand, most febrile seizures would remit spontaneously with age and might be missed by the IEM, PEPD, SFN and CIP patients and their doctors. It is suggested that IEM, PEPD, SFN and CIP patients with SCN9A mutations should be reinvestigated for their possible history of seizure disorders, which might help to further confirm the role of SCN9A in seizure disorders. This report expands the genotypephenotype spectrum that the Q10R mutation in SCN9A gene is associated with both IEM and GEFS+, and it affects both peripheral and central nervous systems.
